[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre National de la Recherche Scientifique, France\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100608318","impact-of-internal-menstrual-protections-on-immunity-and-vaginal-microbiota-100608318",false,"NCT07199998","Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota","Impact of the Use of Internal Menstrual Protections on Immunity and Vaginal Microbiota","CUPS2","Inclusion Criteria:\n\n* Willingness to comply with all study procedures and availability for the duration of the study.\n* Female, aged 18 to 49 years.\n* In general good health, as determined by medical history.\n* Covered by the national health insurance system.\n* Willing to sign a written informed consent form.\n* Has already experienced menstruation prior to the start of the study.\n* No vaginal sexual intercourse within 72 hours before the study visit.\n* Has had at least 6 menstrual periods in the past 12 months.\n\nExclusion Criteria:\n\n* HIV infection.\n* Positive diagnosis for chlamydia or syphilis at screening or within 4 weeks prior to screening.\n* History of hormonal disorders or menstrual cycle irregularities.\n* Metrorrhagia.\n* Pregnancy or breastfeeding.\n* Family members or close relatives of the clinical or scientific team.\n* Treatment with any medication for chronic inflammatory disease or chronic conditions (e.g., cancer, arthritis, transplantation) within the past 12 months.\n* Participation in an ongoing clinical trial.\n* Receiving or having received antibiotic treatment within the 4 weeks prior to the study.\n* Refusal to be informed in case of detected abnormalities.\n* Indistinct use of both tampons and menstrual cups.\n* Never having had vaginal penetrative intercourse.",true,"FEMALE","18 Years","49 Years",{"count":22,"type":23},300,"ESTIMATED","OBSERVATIONAL","The availability, effectiveness, and safety of menstrual protection represent a key public health issue. However, research on women's menstrual and sexual health remains extremely limited. Whether societal or pathological, many hypotheses are emerging regarding the effects of menstrual protection products, yet little attention has been given to the products themselves, their societal role, or their physiological and pathological consequences. Internal menstrual products, such as tampons and menstrual cups, are widely used but are subject to limited regulatory oversight, and few studies have investigated their long-term effects on vaginal health.\n\nThis study aims to investigate how different types of menstrual protection influence vaginal microbiota, immune responses, and the recurrence of gynecological conditions such as bacterial vaginosis, mycosis, or dysbiosis. Biological samples (vaginal, cervical, urinary, and blood) will be collected to analyze vaginal microbiota composition and local immunity. Participants will be divided into three groups based on their main type of menstrual protection: menstrual cup users, tampon users, and external pad users. The study will compare these groups to assess potential differences in vaginal health and immune response related to menstrual product use.",[27,28,29,30,31,32,33,34],"Sexual Transmitted Disease","Vaginosis, Bacterial","Mycosis","Urogenital Disease","HPV","Dysbiosis","Toxic Shock Syndrome","Menstrual Cup",[36,32,37,38,39,40,41],"Menstrual cup","Menstrual health","Menstrual protection","Menstrual pad","Tampon","Immunity","RECRUITING","2026-04-08",{"date":45,"type":46},"2026-04-09","ACTUAL",{"date":48,"type":46},"2026-04-07",{"date":50,"type":23},"2027-03",{"name":52,"class":53},"Centre National de la Recherche Scientifique, France","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":17,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":5},"100618696","phase-2-synergistic-effect-of-non-invasive-brain-and-spinal-cord-stimulation-100618696","NCT07334977","Synergistic Effect of Non-invasive Brain and Spinal Cord Stimulation","Synergistic Potential of Non-invasive Brain and Spinal Cord Stimulation for Improving Sensorimotor and Cognitive Functions After Neurological Injury","BrainSpineStim","Inclusion Criteria:\n\nCONTROL GROUP:\n\n* Over 18 years of age\n* Participant who has signed an informed consent form\n* Participant who is affiliated with and covered by the social security system\n\nPOST-STROKE GROUP:\n\n* Over 18 years of age\n* Who sustained a stroke more than 3 weeks ago\n* Considered medically stable by the medical investigator\n* Who has signed an informed consent form\n* Affiliated with and covered by the social security system\n\nSCI GROUP:\n\n* Over 18 years of age\n* Considered to have a complete or incomplete spinal cord injury (i.e., with a score on the Spinal Injury Association (ASIA) Impairment Scale (AIS) score from A to D)\n* Considered medically stable by the investigating physician\n* Presenting with quadriplegia due to cervical injury\n* Who has signed an informed consent form\n* Affiliated with and covered by the social security system.\n\nExclusion Criteria:\n\n* Suffering from a chronic condition\n* Skin problems or open wounds\n* History of epilepsy or seizures\n* Presence of a contraindication to the use of magnetic\u002Felectrical stimulation or MRI, including: cardiac pacemaker; implanted hearing aid; intraocular foreign body, shrapnel, or bullets; metal worker; pacemaker or neurostimulator; claustrophobia\n* Presence of implanted medical devices (cardiac valve, endovascular devices, ventricular shunt valve, surgical clips, metallic sutures, staples, stent, osteosynthesis or arthrodesis hardware) not classified as \"MR Conditional\" according to ASTM F2503.\n* Individuals who are legally incompetent, under judicial protection, guardianship, or trusteeship\n* Pregnant and\u002For breastfeeding women\n* Individuals who refuse to be informed of any abnormalities that may be detected by MRI.","ALL",{"count":65,"type":23},45,"INTERVENTIONAL",[68],"PHASE2","The goal of this clinical study is to investigate the potential synergy between non-invasive brain and spinal cord stimulation administered during a cognitive-motor task, in terms of their immediate effects on sensorimotor and cognitive functions after neurological injuries affecting the upper limb (cervical spinal cord injury and stroke). Secondary objectives are to evaluate the relevance of anatomical MRI, functional MRI, and neurophysiological measurements for optimizing and predicting the effects of these different interventions.",[71,72,73],"Stroke","Spinal Cord Injury","Able Bodied",[75,76,77,78,79],"Neuromodulation","Neuroplasticity","transcutaneous Spinal Cord Stimulation","transcranial Direct Current Stimulation","Neuroimaging","2026-01-06",{"date":82,"type":46},"2026-01-12",{"date":84,"type":46},"2024-12-11",{"date":86,"type":23},"2027-12",{"name":52,"class":53},""]